Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBITDA: 2019-2025

Historic EBITDA for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$41.1 million.

  • Allogene Therapeutics' EBITDA rose 37.08% to -$41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$211.9 million, marking a year-over-year increase of 24.54%. This contributed to the annual value of -$256.7 million for FY2024, which is 19.34% up from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' EBITDA is -$41.1 million, which was up 19.42% from -$51.0 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' EBITDA peaked at -$2.1 million during Q4 2021, and registered a low of -$96.0 million during Q1 2023.
  • For the 3-year period, Allogene Therapeutics' EBITDA averaged around -$66.1 million, with its median value being -$65.0 million (2024).
  • Its EBITDA has fluctuated over the past 5 years, first surged by 98.46% in 2021, then slumped by 4,424.39% in 2022.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' EBITDA stood at -$2.1 million in 2021, then plummeted by 4,424.39% to -$94.2 million in 2022, then increased by 10.53% to -$84.3 million in 2023, then rose by 28.62% to -$60.2 million in 2024, then spiked by 37.08% to -$41.1 million in 2025.
  • Its EBITDA was -$41.1 million in Q3 2025, compared to -$51.0 million in Q2 2025 and -$59.6 million in Q1 2025.